Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by MrMonkon Aug 29, 2013 8:18am
158 Views
Post# 21705612

RE:Financials...

RE:Financials...My guess - and this is simply an educated guess - is that they have another potential partner lined up.  They have a large (overall) prospective property to explore and I'm wondering if they intend to use their own funds to drill some other targets within their land package.  As for Marban, apparently others are interested (and why wouldn't they be?) and I suspect NOX will put together another deal.  It won't happen overnight, but it shouldn't come as a shock to anyone if a larger company with an interest in the area steps up.  Discussions are probably already underway.

I'm not sure I understand your comment "...unlikely to get anything that sweet again.".  Early-stage explorers generally need to give MORE away to attract a re*****ble partner because of the prospective nature of a project.  Now being at a more advanced stage - with an attractive project that has been to a significant degree de-risked - would they not be able to negotiate a BETTER deal for themselves?  It seems logical to me but I would like to hear why you think they will only be able to cut a less attractive deal (relative to the original one).

-- MM
<< Previous
Bullboard Posts
Next >>